175 related articles for article (PubMed ID: 11571244)
1. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.
Moore DF; Scott LT; Gladwin MT; Altarescu G; Kaneski C; Suzuki K; Pease-Fye M; Ferri R; Brady RO; Herscovitch P; Schiffmann R
Circulation; 2001 Sep; 104(13):1506-12. PubMed ID: 11571244
[TBL] [Abstract][Full Text] [Related]
2. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
Moore DF; Altarescu G; Ling GS; Jeffries N; Frei KP; Weibel T; Charria-Ortiz G; Ferri R; Arai AE; Brady RO; Schiffmann R
Stroke; 2002 Feb; 33(2):525-31. PubMed ID: 11823664
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.
Moore DF; Altarescu G; Herscovitch P; Schiffmann R
BMC Neurol; 2002 Jun; 2():4. PubMed ID: 12079501
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
5. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
[TBL] [Abstract][Full Text] [Related]
8. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
10. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
11. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
12. Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression.
Meng XL; Arning E; Wight-Carter M; Day TS; Jabbarzadeh-Tabrizi S; Chen S; Ziegler RJ; Bottiglieri T; Schneider JW; Cheng SH; Schiffmann R; Shen JS
J Inherit Metab Dis; 2018 Mar; 41(2):231-238. PubMed ID: 29110178
[TBL] [Abstract][Full Text] [Related]
13. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease--a diagnostic and therapeutic problem.
Strujić BJ; Jeren T
Ren Fail; 2005; 27(6):783-6. PubMed ID: 16350834
[TBL] [Abstract][Full Text] [Related]
15. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.
Shah JS; Elliott PM
Acta Paediatr Suppl; 2005 Mar; 94(447):11-4; discussion 9-10. PubMed ID: 15895705
[TBL] [Abstract][Full Text] [Related]
17. Narrative review: Fabry disease.
Clarke JT
Ann Intern Med; 2007 Mar; 146(6):425-33. PubMed ID: 17371887
[TBL] [Abstract][Full Text] [Related]
18. [Neurological aspects of Fabry disease].
Clavelou P; Besson G
Presse Med; 2007 Mar; 36 Spec No 1():1S65-8. PubMed ID: 17546771
[TBL] [Abstract][Full Text] [Related]
19. [Neurological manifestations of Fabry disease].
Mendióroz M; Fernández-Cadenas I; Montaner J
Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
[TBL] [Abstract][Full Text] [Related]
20. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]